BIIB

BIIB

USD

Biogen Inc. Common Stock

$124.990-4.560 (-3.520%)

Preço em tempo real

Healthcare
Drug Manufacturers - General
Estados Unidos

Gráfico de preços

Loading Chart...

Métricas-chave

Métricas de mercado
Fundamentos da empresa
Estatísticas de negociação

Métricas de mercado

Abertura

$129.550

Máximo

$129.580

Mínimo

$124.680

Volume

1.14M

Fundamentos da empresa

Capitalização de mercado

18.3B

Setor

Drug Manufacturers - General

País

United States

Estatísticas de negociação

Volume médio

1.48M

Bolsa de valores

NMS

Moeda

USD

Faixa de 52 semanas

Mínimo $110.04Atual $124.990Máximo $236.48

Notícias relacionadas

GlobeNewswire

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy

Global Phase 3 PROMINENT study will evaluate the efficacy and safety of felzartamab, as compared to tacrolimus, in adults with primary membranous nephropathy (PMN)There are currently no therapies specifically approved

Ver mais
Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy
GlobeNewswire

New Data for Nusinersen Underscore Biogen's Commitment to Advancing Clinical Research to Improve Outcomes in SMA

New analyses from DEVOTE Part C further characterize the improvements in motor function in participants with SMA who transitioned to the investigational higher dose regimen of nusinersen from 12 mg SPINRAZA®

Ver mais
New Data for Nusinersen Underscore Biogen's Commitment to Advancing Clinical Research to Improve Outcomes in SMA
Analyst Upgrades

RBC Capital Reiterates Outperform on Biogen, Maintains $213 Price Target

RBC Capital analyst Brian Abrahams reiterates Biogen with a Outperform and maintains $213 price target.

Ver mais
RBC Capital Reiterates Outperform on Biogen, Maintains $213 Price Target
Analyst Upgrades

HC Wainwright & Co. Reiterates Buy on Biogen, Maintains $187 Price Target

HC Wainwright & Co. analyst Andrew Fein reiterates Biogen with a Buy and maintains $187 price target.

Ver mais
HC Wainwright & Co. Reiterates Buy on Biogen, Maintains $187 Price Target
GlobeNewswire

Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results

Salanersen (BIIB115/ION306) is a novel antisense oligonucleotide (ASO) with the potential to achieve high efficacy and once yearly dosing in spinal muscular atrophy (SMA)Interim Phase 1 data show children with SMA

Ver mais
Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results
Analyst Upgrades

Piper Sandler Reiterates Neutral on Biogen, Maintains $115 Price Target

Piper Sandler analyst David Amsellem reiterates Biogen with a Neutral and maintains $115 price target.

Analyst Upgrades

Wedbush Reiterates Neutral on Biogen, Maintains $121 Price Target

Wedbush analyst Laura Chico reiterates Biogen with a Neutral and maintains $121 price target.

Mantenha-se atualizado

Defina um alerta de preço, obtenha atualizações de análise de IA e notícias de mercado em tempo real.